This most recent twist in the Lykos Therapeutics saga threatens a major overhaul of the organization’s tactic and route, with Musk ally and billionaire investor Antonio Gracias showing up to choose to choose the business back again toward its nonprofit drug advancement roots and a far more Doblinite philosophy.“NeonMind’s proprietary preclini